Ed P. F. IJzerman

Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study.

BACKGROUND Pneumococcal conjugate vaccine prevents recurrent acute otitis media (AOM) in infants immunised at 2, 4, 6, and 12-15 months of age. We aimed to find out whether this vaccine also prevents AOM in older children who have had previous episodes of AOM. METHODS In this double-blind, randomised study, we enrolled 383 patients aged 1-7 years who had had two or more episodes of AOM in the year before entry. Randomisation was stratified in four groups according to age (12-24 months vs 25-84 months) and the number of previous AOM episodes (two or three episodes vs four or more episodes). Children received either 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine, or hepatitis A or B vaccines. They were followed up for 18 months for recurrence of AOM. We also cultured samples of middle-ear fluid and nasopharyngeal swabs to assess association of pneumococcal serotypes with AOM after vaccination. FINDINGS We noted no reduction of AOM episodes in the pneumococcal vaccine group compared with controls (intention-to-treat analysis: rate ratio 1.25, 95% CI 0.99-1.57). Although nasopharyngeal carriage of pneumococci of serotypes included in the conjugate-vaccine was greatly reduced after pneumococcal vaccinations, immediate and complete replacement by non-vaccine pneumococcal serotypes took place. INTERPRETATION These data do not lend support to the use of pneumococcal conjugate vaccine to prevent otitis media in previously unvaccinated toddlers and children with a history of recurrent AOM.

Effect of Reduced-Dose Schedules With 7-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Pneumococcal Carriage in Children: A Randomized Controlled Trial

CONTEXT The effects of reduced-dose schedules of 7-valent pneumococcal conjugate vaccine (PCV-7) on pneumococcal carriage in children are largely unknown, although highly relevant in the context of subsequent herd effects. OBJECTIVE To examine the effects of a 2-dose and 2 + 1-dose PCV-7 schedule on nasopharyngeal pneumococcal carriage in young children compared with controls. DESIGN, SETTING, AND PATIENTS A randomized controlled trial of nasopharyngeal carriage of Streptococcus pneumoniae enrolling 1003 healthy newborns and 1 of their parents in a general community in The Netherlands, with follow-up to age 24 months and conducted between July 7, 2005, and February 14, 2008. INTERVENTION Infants were randomly assigned to receive 2 doses of PCV-7 at 2 and 4 months; 2 + 1 doses of PCV-7 at 2, 4, and 11 months; or no dosage (control group). MAIN OUTCOME MEASURE Vaccine serotype pneumococcal carriage rates in infants in the second year of life. RESULTS At 12 months, vaccine serotype pneumococcal carriage was significantly decreased after both PCV-7 schedules, with vaccine serotype pneumococcal carriage rates of 25% (95% confidence interval [CI], 20%-30%) and 20% (95% CI, 16%-25%) in the 2-dose and 2 + 1-dose schedule groups, respectively, vs 38% (95% CI, 33%-44%) in the control group (both P < .001). At 18 months, in the 2 + 1-dose schedule group, vaccine serotype pneumococcal carriage had further decreased to 16% (95% CI, 12%-20%) and, at 24 months, to 14% (95% CI, 11%-18%; both P < .001); whereas in the 2-dose schedule group, vaccine serotype pneumococcal carriage had remained stable at 18 months (24%; 95% CI, 20%-29%), but at 24 months had further decreased to 15% (95% CI, 11%-19%; both P < .001). In the control group, vaccine serotype pneumococcal carriage remained around 36% to 38% until 24 months. CONCLUSION Compared with no pneumococcal vaccination, a 2 + 1-dose and 2-dose schedule of PCV-7 resulted in significant reductions of vaccine serotype pneumococcal carriage in the second year of life. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00189020.

Effects of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugate Vaccine on Nasopharyngeal Bacterial Colonization in Young Children: A Randomized Controlled Trial

This study evaluated effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiDCV) compared with the 7-valent vaccine on nasopharyngeal bacterial colonization, specifically nontypeable Haemophilus influenzae (NTHi). PHiD-CV had no differential effect on nasopharyngeal NTHi colonization.

Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media

BACKGROUND We recently showed that vaccination with a 7-valent pneumococcal conjugate vaccine (PCV7) followed by a 23-valent pneumococcal polysaccharide vaccine (PPSV23) failed to prevent new episodes of acute otitis media (AOM) in previously unvaccinated toddlers and children with a history of recurrent AOM. We describe in detail the impact of pneumococcal vaccinations on nasopharyngeal carriage of S. pneumoniae in this study population. METHODS The impact of vaccination with PCV7 followed by PPSV23 on pneumococcal nasopharyngeal carriage was studied in a prospective, randomized trial involving 383 children (age range, 1-7 years) with previous AOM. Nasopharyngeal swab specimens were collected at the time of first vaccination and at 6-7-month intervals during the 26-month follow-up period. RESULTS Overall, pneumococcal carriage rates did not diminish, remaining at approximately 50% in both PCV7/PPSV23 and control vaccinees. A significant shift from conjugate vaccine- to nonconjugate vaccine-type pneumococci was observed in children aged 1-2 years, who received the conjugate vaccine twice before the polysaccharide vaccine was administered. Conjugate vaccine serotype carriage was not influenced in older children, who received the conjugate vaccine once before receiving the polysaccharide booster. CONCLUSIONS The administration of conjugate vaccines at least twice also after 2 years of age may be mandatory for reducing the carriage of conjugate vaccine serotypes in children with recurrent AOM. Polysaccharide booster vaccination did not affect nasopharyngeal colonization with serotypes not included in the conjugate vaccine.

Wild-type MIC distribution and epidemiological cut-off values in clinical Legionella pneumophila serogroup 1 isolates.

OBJECTIVES The purpose of this study was to establish wild-type (WT) distributions and determine the epidemiological cut-off values (ECOFF) in clinical L. pneumophila serogroup 1 isolates for 10 antimicrobials commonly used for the treatment of Legionella infections using a method feasible in a routine clinical laboratory. METHODS MICs of 183 clinical L. pneumophila serogroup 1 isolates, collected as part of an outbreak detection program, were tested using E-test methodology on buffered charcoal yeast extract agar supplemented with α-ketoglutarate (BCYE-α). The MICs were read after 2 days of incubation at 35 °C with increased humidity and without CO(2). ECOFFs were determined according to EUCAST methodology and expressed as WT ≤ X mg/L. RESULTS All antimicrobials showed a WT distribution, although the width varied from 2 two-fold dilutions to 8 dilutions, depending on antibiotic class. The ECOFFs determined were 1.0 mg/L for ciprofloxacin, 0.50 mg/L for levofloxacin, 1.0 mg/L for moxifloxacin, 1.0 mg/L for erythromycin, 1.0 mg/L for azithromycin, 0.50 mg/L for clarithromycin, 1.0 mg/L for cefotaxime, 0.032 mg/L for rifampicin, 16 mg/L for tigecycline, and 8 mg/L for doxycycline. CONCLUSION All isolates were inhibited by low concentrations of the fluoroquinolones and macrolides tested, with somewhat higher MICs for the fluoroquinolones. Rifampicin was found to be the most active against L. pneumophila isolates in vitro. These data can be used as a reference for the detection of resistance in clinical L. pneumophila isolates and as a setting of clinical breakpoints.

Isolation of ciprofloxacin-resistant Legionella pneumophila in a patient with severe pneumonia

Sir, Legionella species are responsible for 1%– 5% of cases of community-acquired pneumonia. Legionella pneumophila serogroup 1 (SG1) accounts for .90% of Legionnaires’ disease (LD) in North America and Europe and is the cause of significant mortality. The mortality rate among patients with L. pneumophila infections continues to be high, up to 26%. The antimicrobial agents most commonly used for treatment of LD are fluoroquinolones (e.g. ciprofloxacin or levofloxacin) and macrolides. In recent studies, we established wild-type distributions and determined the epidemiological cut-off values (ECOFFs) in clinical L. pneumophila SG1 isolates for 10 antimicrobials commonly used for the treatment of Legionella infections. A patient sought care at his general practitioner after several days of falling and body pains. On examination, the patient appeared ill and was sent to the emergency department of a nearby hospital. The initial chest radiograph demonstrated an infiltrate of the left lower lung field. The patient was admitted to the intensive care unit. Blood cultures were taken and antibiotic treatment was started with cefazolin and gentamicin. Urine was examined for the presence of Legionella antigens and when this test was reported positive, treatment was switched to 400 mg of ciprofloxacin intravenously twice daily. After initial improvement the clinical condition of the patient deteriorated, leading to intubation and mechanical ventilation. A new chest radiograph revealed a diffuse interstitial pneumonia. Bronchoalveolar lavage (BAL) was performed 4 days after treatment with ciprofloxacin was started and the patient slowly recovered. Eventually, culture of the BAL grew L. pneumophila SG1 after 4 days of ciprofloxacin treatment. After 10 days, the patient could be transferred to the ward. Therapy was then switched to 500 mg of clarithromycin orally twice daily. The patient’s further recovery was uncomplicated. The L. pneumophila SG1 strain was sent, as part of a national Legionella outbreak detection programme, to the reference laboratory for Legionella in Haarlem, The Netherlands. Susceptibility testing for ciprofloxacin was performed with Etest and an MIC value of ciprofloxacin of 2 mg/L was found. This value is outside the wild-type distribution range ECOFF1⁄41 mg/L as previously described and therefore potentially resistant. For sequencing of gyrA and gyrB (DNA gyrase) and parC and parE (topoisomerase IV) genes, extraction of L. pneumophila DNA was performed. The DNA extraction was performed by use of Qiagen’s BioRobot EZ1 (Hilden, Germany) according to the manufacturer’s instructions. The sequencing reaction was performed twice by using primer systems previously described for the L. pneumophila SG1 strain Paris. A comparative analysis of the obtained sequences was done using the published L. pneumophila genomes and data from the literature describing mutations in the quinolone resistance-determining region (QRDR) of type II topoisomerase of L. pneumophila by using DNAStar (WI, USA) software and the NCBI database. For control experiments, the wild-type strain MTZ OLDA and a spontaneous quinolone-resistant mutant of this strain were used. MTZ OLDA is an environmental isolate (L. pneumophila SG1), isolated from the water supply of a large building. A point mutation in the QRDR of the gyrA gene was identified and this mutation led to an amino acid exchange at position 83 (Escherichia coli numbering system). The result of this amino acid exchange is a change in ciprofloxacin susceptibility. Mutation at the same position (amino acid 83) has also been reported for other spontaneous quinolone-resistant mutants (Table 1). It is known that, in general, pathogens can become resistant during the course of a patient’s therapy and also induction of resistance upon exposure to antibiotics has been described. The origin of resistance in the clinical isolate is as yet unclear. There are two possibilities. The first is that the patient contracted an L. pneumophila SG1 strain with this point mutation from the environment. Alternatively, the mutation occurred during the Research letters

Evaluation of the Oxoid Xpect Legionella Test Kit for Detection of Legionella pneumophila Serogroup 1 Antigen in Urine

ABSTRACT We evaluated a new immunochromatographic assay (Oxoid Xpect Legionella test kit) for the ability to detect Legionella pneumophila serogroup 1 antigen in urine. The results were compared with those obtained with the Binax NOW urinary antigen test by following the manufacturers’ instructions. The sensitivities and specificities were estimated to be 89 and 100%, respectively, for the Oxoid Xpect Legionella test kit and 86 and 100%, respectively, for the Binax NOW test.

Correlation of MIC value and disk inhibition zone diameters in clinical Legionella pneumophila serogroup 1 isolates

OBJECTIVES Routine use of disk diffusion tests for detecting antibiotic resistance in Legionella pneumophila has not been described. The goal of this study was to determine the correlation of MIC values and inhibition zone diameter (MDcorr) in clinical L. pneumophila isolates. METHODS Inhibition zone diameter of 183 L. pneumophila clinical isolates were determined for ten antimicrobials. Disk diffusion results were correlated with MICs as determined earlier with E-tests. RESULTS Overall the correlation of MIC values and inhibition zone diameters (MDcorr) of the tested antimicrobials is good, and all antimicrobials showed a WT distribution. Of the tested fluoroquinolones levofloxacin showed the best MDcorr. All macrolides showed a wide MIC distribution and good MDcorr. The MDcorr for cefotaxim, doxycycline and tigecycline was good, while for rifampicin and moxifloxacin, they were not. CONCLUSION Overall good correlation between MIC value and disk inhibition zone were found for the fluoroquinolones, macrolides and cefotaxim.